These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33989225)

  • 1. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.
    John BV; Khakoo NS; Schwartz KB; Aitchenson G; Levy C; Dahman B; Deng Y; Goldberg DS; Martin P; Kaplan DE; Taddei TH
    Am J Gastroenterol; 2021 Sep; 116(9):1913-1923. PubMed ID: 33989225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis.
    John BV; Aitcheson G; Schwartz KB; Khakoo NS; Dahman B; Deng Y; Goldberg D; Martin P; Taddei TH; Levy C; Kaplan DE
    Hepatology; 2021 Aug; 74(2):879-891. PubMed ID: 33636012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis.
    John BV; Dahman B; Deng Y; Khakoo NS; Taddei TH; Kaplan DE; Levy C
    Liver Int; 2022 Feb; 42(2):384-393. PubMed ID: 34614294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Harms MH; de Veer RC; Lammers WJ; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Trivedi PJ; Hirschfield GM; Pares A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Hansen BE; Buuren HRV; van der Meer AJ
    Gut; 2020 Aug; 69(8):1502-1509. PubMed ID: 31843787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
    J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.
    Melchor-Mendoza YK; Martínez-Benítez B; Mina-Hawat A; Rodríguez-Leal G; Duque X; Moran-Villota S
    Ann Hepatol; 2017; 16(3):430-435. PubMed ID: 28425413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased infiltration of CD4
    Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
    Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; Adang RP; van Nieuwkerk CM; Timmer R; Drenth JP; Spoelstra P; Brouwer HT; Kuyvenhoven JP; van Buuren HR;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1495-502. PubMed ID: 21389798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
    Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
    J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular Carcinoma in Primary Biliary Cholangitis.
    Sy AM; Ferreira RD; John BV
    Clin Liver Dis; 2022 Nov; 26(4):691-704. PubMed ID: 36270724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis.
    Shi TY; Zhang LN; Chen H; Wang L; Shen M; Zhang X; Zhang FC
    World J Gastroenterol; 2013 Feb; 19(7):1111-8. PubMed ID: 23467321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy.
    Ampuero J; Lucena A; Berenguer M; Hernández-Guerra M; Molina E; Gómez-Camarero J; Valdivia C; Gómez E; Casado M; Álvarez-Navascuez C; Jorquera F; García-Buey L; Díaz-González Á; Morillas R; García-Retortillo M; Sousa JM; Pérez-Medrano I; Simón MÁ; Martínez J; Arenas J; Londoño MC; Olveira A; Fernández-Rodríguez C;
    Hepatology; 2024 Oct; 80(4):791-806. PubMed ID: 38447019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between serum soluble CD14 and IL-8 levels and clinical outcome in primary biliary cholangitis.
    Umemura T; Sekiguchi T; Joshita S; Yamazaki T; Fujimori N; Shibata S; Ichikawa Y; Komatsu M; Matsumoto A; Shums Z; Norman GL; Tanaka E; Ota M
    Liver Int; 2017 Jun; 37(6):897-905. PubMed ID: 27860118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.
    Örnolfsson KT; Lund SH; Olafsson S; Bergmann OM; Björnsson ES
    Scand J Gastroenterol; 2019 May; 54(5):609-616. PubMed ID: 31074667
    [No Abstract]   [Full Text] [Related]  

  • 18. Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis.
    Gordon SC; Wu KH; Lindor K; Bowlus CL; Rodriguez CV; Anderson H; Boscarino JA; Trudeau S; Rupp LB; Haller IV; Romanelli RJ; VanWormer JJ; Schmidt MA; Daida YG; Sahota A; Vincent J; Zhang T; Li J; Lu M;
    Am J Gastroenterol; 2020 Feb; 115(2):262-270. PubMed ID: 31985529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis.
    Hofer BS; Burghart L; Halilbasic E; Simbrunner B; Petrenko O; Mandorfer M; Stättermayer AF; Trauner M; Reiberger T
    Aliment Pharmacol Ther; 2024 Apr; 59(8):962-972. PubMed ID: 38409879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.
    Chen S; Duan W; Li M; Li S; Lv T; Tian Q; Wang Q; Wu X; Zhao X; Wang X; Wang Y; Kong Y; Ma H; Ou X; You H; Jia J
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1236-1241. PubMed ID: 30365184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.